CHMP opinion on sepiapterin MAA expected in Q2 2025. FDA approval decision on sepiapterin NDA expected July 29, 2025. Results from the PIVOT-HD Phase 2 study of PTC518 expected in Q2 2025. NDA acceptance of vatiquinone expected in Q1 2025, with potential regulatory approval in 2H 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics sees FY25 revenue $600M-$800M
- PTC Therapeutics sees FY25 revenue $600M-$800M, consensus $963.31M
- PTC Therapeutics sees FY24 revenue ~$814M, consensus $795.38M
- PTC Therapeutics price target lowered to $58 from $63 at RBC Capital
- PTC Therapeutics submits NDA for vatiquinone in Friedreich ataxia